Browse by author
Lookup NU author(s): Yuzhe Shi, Melanie Beckett, Dr Helen Blair, Dr Ricky Tirtakusuma, Dr Sirintra Nakjang, Dr Amir EnshaeiORCiD, Dr Frederik van DelftORCiD
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
T-cell Acute Lymphoblastic Leukemia (T-ALL) is frequently characterized by glucocorticoid (GC) resistance, which is associated with inferior outcomes, thus highlighting the need for novel therapeutic approaches for GC resistant T-ALL. The pTCR/TCR signaling pathways play a critical role in cell fate decisions during physiological thymocyte development, with an interplay between TCR and glucocorticoid receptor (GR) signaling determining the T-lymphocyte selection process. We performed an shRNA screen in vitro and in vivo in T-ALL cell lines and patient derived xenograft (PDX) samples to identify vulnerabilities in the pTCR/TCR pathway and identified a critical role for the kinase LCK in cell proliferation. LCK knockdown or inhibition with dasatinib (DAS) caused cell cycle arrest. Combination of DAS with dexamethasone (DEX) resulted in significant drug synergy leading to cell death. The efficacy of this drug combination was underscored in a randomized phase II-like murine trial, recapitulating an early phase human clinical trial. T-ALL expansion in immunocompromised mice was significantly impaired using this drug combination, relative to mice receiving control vehicle or single drug treatment, highlighting the immediate clinical relevance of this drug combination for high risk T-ALL patients. Our results thus provide a strategy to improve the efficacy of current chemotherapy platforms and circumvent GC resistance.
Author(s): Shi Y, Beckett MC, Blair HJ, Tirtakusuma R, Nakjang S, Enshaei A, Halsey C, Vormoor J, Heidenreich O, Krippner-Heidenreich A, van Delft FW
Publication type: Article
Publication status: Published
Journal: Haematologica
Year: 2021
Volume: 106
Issue: 4
Pages: 1056-1066
Print publication date: 01/04/2021
Online publication date: 05/03/2020
Acceptance date: 04/03/2020
Date deposited: 22/04/2020
ISSN (print): 0390-6078
ISSN (electronic): 1592-8721
Publisher: Fondazione Ferrata Storti
URL: https://doi.org/10.3324/haematol.2019.241026
DOI: 10.3324/haematol.2019.241026
Altmetrics provided by Altmetric